Incidence and Clinical Outcomes of Vitamin D Status and Myeloma Bone Disease Among Patients With Newly Diagnosed Multiple Myeloma (MM) in a Tropical Country-Retrospective Cohort Study.

OBJECTIVE: The retrospective data analysis on 80 patients from 2018 to 2022 aimed to determine the incidence and clinical outcomes of vitamin D status and myeloma bone disease among newly diagnosed multiple myeloma (MM) patients in Singapore. METHOD: Patients' demographics, bone health data and bone disease management were collected. Chi-square test was conducted to compare variables between patients who survived versus those who demised. Survival differences were compared using log-rank analysis and plotted using Kaplan-Meier estimates. Multivariable survival analysis was conducted using Cox Regression. RESULTS: Fifty-nine (73.8%) patients had myeloma bone disease at diagnosis, and 42 (71.2%) of these patients had skeletal-related adverse events at diagnosis. The compliance to bone health management needs to be optimized, as only 70 patients had their vitamin D level tested at diagnosis, of which 48 (68.7%) patients were vitamin D insufficient or deficient. Bone disease data did not correlate with mortality. Higher mortality was initially observed among patients with non-Chinese (p = 0.03), R-ISS 3 (p = 0.001), and renal involvement at diagnosis (p = 0.035). R-ISS staging remained the only statistically significant variable after adjusting for race (adjusted HR 3.99; 95% CI 1.58-10.07). CONCLUSION: The study found no correlation between myeloma bone health data and survival outcomes in our centre.